Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eidos Therapeutics Inc (EIDX)

Eidos Therapeutics Inc (EIDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,573,840
  • Shares Outstanding, K 36,884
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,290 K
  • 60-Month Beta -0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 12.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.45
  • Number of Estimates 4
  • High Estimate -0.41
  • Low Estimate -0.51
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -55.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.00 +64.25%
on 08/05/19
46.44 -0.98%
on 08/22/19
+9.46 (+25.90%)
since 07/22/19
3-Month
24.50 +87.71%
on 06/25/19
46.44 -0.98%
on 08/22/19
+18.50 (+67.30%)
since 05/22/19
52-Week
8.89 +417.32%
on 10/04/18
46.44 -0.98%
on 08/22/19
+27.20 (+144.76%)
since 08/22/18

Most Recent Stories

More News
EIDX Crosses Above Average Analyst Target

In recent trading, shares of Eidos Therapeutics Inc have crossed above the average analyst 12-month target price of $44.33, changing hands for $45.00/share. When a stock reaches the target an analyst...

EIDX : 45.99 (+7.78%)
Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares

--Advises Stockholders Take No Action at this Time

EIDX : 45.99 (+7.78%)
Eidos Therapeutics Reports Second Quarter 2019 Financial Results

Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), today reported its financial results for the second quarter ended June 30, 2019 and provided an update on the company's recent achievements.

EIDX : 45.99 (+7.78%)
Eidos Therapeutics Reports First Quarter 2019 Financial Results

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the first quarter ended March 31, 2019 and provided an update on the company's recent achievements.

EIDX : 45.99 (+7.78%)
Research Report Identifies National General, Eidos Therapeutics, Auris Medical Holding AG, and Realogy with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of National General Holdings Corp...

NGHC : 23.83 (+0.76%)
EIDX : 45.99 (+7.78%)
RLGY : 6.45 (+2.06%)
EARS : 2.72 (unch)
Eidos Therapeutics to Present at Two Upcoming Investor Conferences

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will present at two upcoming investor conferences.

EIDX : 45.99 (+7.78%)
Eidos Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results

Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the fourth quarter and full year ended December 31, 2018 and provided an update on the company's recent achievements....

EIDX : 45.99 (+7.78%)
RM LAW Announces an Investigation of Eidos Therapeutics, Inc.

RM LAW, P.C. announces an investigation on behalf of Eidos Therapeutics, Inc. (NASDAQ: EIDX) ("Eidos Therapeutics" or the "Company") investors concerning the Company and its officers' possible violations...

EIDX : 45.99 (+7.78%)
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eidos Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eidos Therapeutics, Inc. ("Eidos" or "the Company")...

EIDX : 45.99 (+7.78%)
Bragar Eagel & Squire, P.C. is Investigating Eidos Therapeutics, Inc. (EIDX) on Behalf of Stockholders and Encourages EIDX Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against Eidos Therapeutics, Inc. (NASAQ: EIDX). Our investigation concerns whether Eidos has violated the federal securities laws and/or engaged...

EIDX : 45.99 (+7.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade EIDX with:

Business Summary

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.

See More

Key Turning Points

2nd Resistance Point 48.68
1st Resistance Point 47.34
Last Price 45.99
1st Support Level 43.75
2nd Support Level 41.51

See More

52-Week High 46.44
Last Price 45.99
Fibonacci 61.8% 32.10
Fibonacci 50% 27.67
Fibonacci 38.2% 23.24
52-Week Low 8.89

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar